Welcome to our dedicated page for ESTABLISHMENT LABS HOLDINGS SEC filings (Ticker: ESTA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Establishment Labs Holdings Inc. filings document regulatory disclosures for a British Virgin Islands medical technology issuer listed on Nasdaq. Its Form 8-K reports cover operating results and financial condition, preliminary financial information, Regulation FD presentation materials, credit-agreement amendments, senior secured term-loan obligations, and other material definitive agreements.
The company’s proxy materials disclose board matters, executive compensation, equity awards, shareholder voting items, and governance practices. Together, the filings describe the Motiva-focused breast aesthetics and reconstruction business, capital structure, debt arrangements, forward-looking-statement disclosures, and recurring corporate reporting obligations.
SCHUTTER EDWARD J reported acquisition or exercise transactions in this Form 4 filing.
ESTABLISHMENT LABS HOLDINGS INC. director Edward J. Schutter received 330 common shares on March 31, 2026 as a share-based retainer. The shares were issued under the company’s 2018 Equity Incentive Plan instead of a quarterly cash retainer, based on the closing share price for the quarter’s last trading day.
After this grant, Schutter directly holds 138,602 common shares, so the award represents a small, routine addition to his existing stake rather than an open-market purchase or sale.
Custin Ann reported acquisition or exercise transactions in this Form 4 filing.
ESTABLISHMENT LABS HOLDINGS INC. director Custin Ann reported receiving a grant of 363 common shares. The shares were awarded in lieu of a quarterly cash retainer under the company’s Outside Director Compensation Policy, based on a closing price of $56.78 per share.
After this equity award issued pursuant to the 2018 Equity Incentive Plan, Custin Ann directly holds a total of 21,732 common shares.
Establishment Labs Holdings Inc. director Juan Jose Chacón Quirós reported an indirect open-market sale of 3,575 common shares at a weighted average price of $60.075 per share. The shares were sold by Sariel Group Ltd. under a pre-arranged Rule 10b5-1 trading plan.
After the sale, indirect holdings reported for Sariel Group Ltd. totaled 1,220,004 common shares, and Chacón Quirós also reported 45,193 common shares held directly. He disclaims beneficial ownership of shares held by Sariel Group Ltd. except to the extent of his pecuniary interest.
ESTABLISHMENT LABS HOLDINGS INC. director Juan Jose Chacon Quiros reported a mix of entity restructuring and open-market sales of Common Shares. A total of 179,240 shares moved from his direct holdings to Sariel Group Ltd. in an exempt transfer, leaving him with 45,193 shares held directly.
Through Sariel Group Ltd., an entity in which he is a shareholder with voting and dispositive power, 33,925 shares were sold in open-market transactions on March 23, 2026 at prices generally between $60.00 and $63.01 per share under a Rule 10b5-1 trading plan. Following these transactions, 1,225,292 shares are reported as held indirectly via Sariel Group Ltd.
ESTABLISHMENT LABS HOLDINGS INC. Chief Financial Officer Cassandra Harris received new equity awards as part of her compensation. She was granted stock options for 12,877 common shares at an exercise price of $74.60 per share and a separate grant of 7,372 common shares.
Both awards vest over four years. One-fourth of the stock units and one-fourth of the option shares will vest on March 9, 2027, with additional one-fourth increments vesting on each one-year anniversary thereafter, as long as she continues as a service provider. Following these awards, she holds 12,877 options and 7,372 common shares directly.
ESTABLISHMENT LABS HOLDINGS INC. executive Cassandra Harris, the company’s Chief Financial Officer, has filed an initial Form 3 insider ownership report. This filing lists her as an officer but does not report any insider transactions or share movements, serving as a baseline disclosure of her status.
Establishment Labs Holdings Inc. reported that General Counsel and Chief Compliance Officer Samuel Ross Mansbach had 657 common shares withheld on March 6, 2026 to cover tax obligations tied to vesting restricted stock units. These shares were valued at $70.41 per share. After this tax-withholding disposition, he held 18,663 common shares directly.
Establishment Labs Holdings Inc. reported that its General Counsel and Chief Compliance Officer, Samuel Ross Mansbach, received equity awards on February 16, 2026. He was granted stock options for 7,131 shares at an exercise price of $0.00 and 4,082 common shares as stock units.
According to the award terms, one-fourth of the stock units and one-fourth of the option shares vest on February 16, 2027, with additional one-fourth portions vesting on each one-year anniversary thereafter. Vesting is conditioned on Mansbach continuing as a service provider through each applicable vesting date.
Establishment Labs Holdings Inc. director and Chief Executive Officer Filippo Caldini reported equity awards on February 18, 2026. He was granted 14,275 stock options with a right to buy shares at an exercise price of $0.00, along with 8,185 common shares as stock units under the 2018 Equity Incentive Plan.
According to the award terms, one-fourth of both the stock units and the option shares will vest on February 18, 2027, with the remaining portions vesting in equal annual installments on each one-year anniversary thereafter, provided he continues as a service provider through each vesting date.